Comparative Pharmacology
Head-to-head clinical analysis: DEXILANT SOLUTAB versus LANSOPRAZOLE AMOXICILLIN AND CLARITHROMYCIN COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXILANT SOLUTAB versus LANSOPRAZOLE AMOXICILLIN AND CLARITHROMYCIN COPACKAGED.
DEXILANT SOLUTAB vs LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Lansoprazole is a proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system (proton pump) at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Clarithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
30 mg orally once daily for 4-8 weeks; for non-erosive GERD, 30 mg orally once daily for 4 weeks; for erosive esophagitis, 60 mg orally once daily for up to 8 weeks; for maintenance of healed EE and relief of heartburn, 30 mg orally once daily. Administer without regard to food; dissolve tablet in water.
Each dose: Lansoprazole 30 mg, Amoxicillin 1000 mg, Clarithromycin 500 mg administered orally twice daily for 10-14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours; however, the pharmacodynamic half-life (duration of acid suppression) is prolonged due to accumulation in parietal cell canaliculi.
Lansoprazole: ~1.5 h (prolonged in hepatic impairment); Amoxicillin: ~1-1.5 h (prolonged in renal impairment); Clarithromycin: ~3-4 h (6-9 h for 14-hydroxy metabolite).
Renal (approx. 53% as metabolites, <2% as unchanged drug), biliary/fecal (approx. 47%).
Lansoprazole: primarily hepatic metabolism, ~33% renal (metabolites), ~67% fecal; Amoxicillin: ~60-80% renal unchanged; Clarithromycin: ~20-30% renal unchanged, ~50% hepatic metabolism, ~30% fecal.
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor